Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Abstract
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.
Overview
CoChat Summary
TL;DR
This study provides in vivo evidence that germline FH and SDH mutations lead to accumulation of Krebs cycle intermediates and HIF1α over-expression in HLRCC and HPGL tumours, supporting pseudo-hypoxic drive as a shared tumorigenic mechanism. It also finds no evidence of increased reactive oxygen species in FH-deficient cells.
Key findings
- FH-deficient fibroblasts and HLRCC fibroids accumulate fumarate and succinate. FH-deficient fibroblast succinate was mean 59.4 mmol/g protein (median 39.8, range 32–125.9) versus controls mean 17.4 (median 14.5, range 9.9–29.8); HLRCC fibroids had succinate 70–98 and fumarate 417–688 mmol/g protein, with succinate:fumarate ratios of 0.10–0.22 versus >1 in myometria.
- SDH-deficient HPGL tumours principally accumulate succinate. SDHB-mutant paragangliomas had succinate 364.5 and 517.0 mmol/g protein versus non-HPGL tumours 32.3–49.7; one SDHB tumour (patient 4) did not show elevated succinate.
- HIF1α over-expression and HIF-target activation were seen in tumours: strong nuclear HIF1α in all HPGL tumours studied (12 paragangliomas and 4 phaeochromocytomas), moderate staining in HLRCC fibroids, and very strong staining in three renal cancers; VEGF expression was high and CD34 showed high microvessel density. Western blotting confirmed a 120 kDa HIF1α band only in tumour, not normal kidney.
- No notable increase in oxidative stress was found: SOD mean was 44.4 versus 38.2 mU/mg and reduced glutathione mean was 5.52 versus 4.04 nmol/mg in FH-deficient versus control cells, with retained mitochondrial complex I, II–III and IV activities.
Methods
- Metabolomic profiling used 1H MRS on skin fibroblasts from four fumarase deficiency patients and six controls, and GC/MS on frozen HLRCC fibroids, myometrium controls, and frozen paragangliomas plus non-HPGL controls.
- Mutation screening of SDHB, SDHC and SDHD was performed by direct sequencing, with array CGH for allelic loss; tumour analyses included HIF1α and CD34 immunohistochemistry, VEGF in situ hybridization, and HIF1α western blotting.
- Samples included HLRCC fibroids and renal cancers, HPGL paragangliomas and phaeochromocytomas, and normal myometrium/kidney controls, all collected with Research Ethics Committee approval.
Limitations
- The paper states that formal statistical analysis was problematic given the small number of samples and lack of information on underlying factors; tumour scarcity also meant duplicate metabolite analysis was not possible.
- The paper notes that one SDHB tumour failed to show elevated succinate for unclear reasons, that HPGL versus other tumour succinate differences were only just significant (P = 0.045) owing to sample 3, and that direct PHD inhibition by fumarate in HLRCC cannot be excluded.
- Evident from the text: HIF1α staining was also weak/moderate in surrounding myometrium, and the oxidative-stress conclusion rests on only two FH-deficient lines for SOD/glutathione assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > INTRODUCTION
What the sources say
- Not checked yetcites [2] Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851. source
- Not checked yetcites [3] Gimm, O., Armanios, M., Dziema, H., Neumann, H.P. and Eng, C. (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res., 60, 6822-6825.
- Not checked yetcites [4] Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270. source
- Partly supportedcites [5] Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54. sourceExperimental — accuracy not yet measured
The Abstract and Results of Astuti et al. (2001) support the SDHB component strongly: inactivating germline SDHB mutations were found in eight families 'segregating pheochromocytoma with or without head and neck paraganglioma' plus one occult germline case, and the SDHD association is stated as background ('pheochromocytoma susceptibility has been associated with germline SDHD mutations'). The SDHC component is not this paper's finding: the Results state 'No pathogenic mutations were identified in SDHC' and 'there was no evidence of germline SDHC mutations in the kindreds with familial pheochromocytoma and paraganglioma', with the SDHC link credited to Niemann and Muller (2000) in the Discussion, and the Abstract hedges that SDHC and SDHD mutations 'may cause hereditary paraganglioma'. So the composite claim (B, C and D, stated as established predisposition) overstates what this source reports for SDHC. (LLM, conf=0.78)
- Not checked yetcites [6] Astuti, D., Douglas, F., Lennard, T.W., Aligianis, I.A., Woodward, E.R., Evans, D.G., Eng, C., Latif, F. and Maher, E.R. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet, 357, 1181-1182. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Partly supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. sourceExperimental — accuracy not yet measured
In “Reactive oxygen species do not play a role in HIF-1α induction after SDH inhibition” (page not available), Selak et al. report no detectable increase in ROS or change in glutathione redox state after SDH inhibition. That supports the statement as applied to the SDH-related HPGL model, but these data do not test the FH-related HLRCC model. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
The Introduction states that HIF prolyl hydroxylases use α-ketoglutarate and convert it to succinate during hydroxylation. In “Succinate is accumulated in SDH-inhibited cells,” the authors propose that accumulated succinate may inhibit this required reaction and impede PHD activity. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
In the section on succinate elevation and HIF-1α stabilization in cells (page unavailable), Selak et al. report that cells treated with a membrane-permeable succinate derivative had elevated HIF-1α levels under normoxic conditions. This supports the attributed in-vitro model; the measured increase was in HIF-1α protein levels, through stabilization. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Pollard et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Pollard et al., 2005
In the citing paper
“For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256).”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [256]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Increased succinate in HPGL tumours
“One SDHB tumour (patient 4) did not show elevated succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Western blotting
“| 4 | No | 32.3 | 3.0 | 10.8 |”
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“Mutations in VHL cause stabilization of the subunits of hypoxia-inducible factor (HIF) (18), which initiates the transcription of genes coding for pro-angiogenic proteins such as VEGF (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 4×
“Recently, support has been provided using an in vitro system for dysfunction of the Krebs cycle leading to the stabilization of HIF (27).”
BackgroundInfluentialMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“Oxidative stress in FH-deficient and control cells was measured using a HPLC method to analyse the oxidation status of the antioxidant glutathione as previously described (33).”
Method[45] Cytochrome oxidase from beef heart mitochondria
Wharton, D. C., & Tzagoloff, A. (1967) · Methods in Enzymology · doi:10.1016/0076-6879(67)10048-7 · Cited by 1,261
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Architecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“SDHB mutations are associated with a higher proportion of malignant lesions and a relatively greater risk of phaeochromocytoma (8).”
Background
Cited by
Items 401–500 of 982
Succinate at the Crossroad of Metabolism and Angiogenesis: Roles of SDH, HIF1α and SUCNR1
Atallah, R., Olschewski, A., & Heinemann, Á. (2022) · Biomedicines · doi:10.3390/biomedicines10123089 · Cited by 47
An overview of nitrile imine based [3+2] cycloadditions over half a decade
Deepthi, A., Acharjee, N., Sruthi, S. L., & Meenakshy, C. B. (2022) · Tetrahedron · doi:10.1016/j.tet.2022.132812 · Cited by 46
Xu, X., Kim, J. J., Li, Y., Xie, J., Shao, C., & Wei, J. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1682-1 · Cited by 46
Reprogramming of central carbon metabolism in hepatocellular carcinoma
Xia, H., Huang, Z., Xu, Y., Yam, J. W. P., & Cui, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113485 · Cited by 46
Clinical and biochemical heterogeneity associated with fumarase deficiency
Ottolenghi, C., Hubert, L., Allanore, Y., Brassier, A., Altuzarra, C., Mellot‐Draznieks, C., Bekri, S., Goldenberg, A., Veyrieres, S., Boddaert, N., et al. (2011) · Human Mutation · doi:10.1002/humu.21534 · Cited by 46
“Pseudohypoxia is defined as the aberrant activation of hypoxia response pathways under normal oxygen conditions (HIF-1alpha/HIF1A and its target genes) and may result from several factors including FH downregulation [Isaacs et al., 2005; Pollard et al., 2005, 2007].”
BackgroundJoberty, G., Böesche, M., Brown, J. A., Eberhard, D., Garton, N. S., Humphreys, P. G., Mathieson, T., Muelbaier, M., Ramsden, N. G., Reader, V., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00080 · Cited by 45
Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
Eason, K., & Sadanandam, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0141 · Cited by 45
Zhou, Z., Ibekwe, E., & Chornenkyy, Y. (2018) · Antioxidants · doi:10.3390/antiox7010016 · Cited by 45
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas
Moog, S., Lussey‐Lepoutre, C., & Favier, J. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0346 · Cited by 45
Schmierer, B., Novák, B., & Schofield, C. J. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-139 · Cited by 45
“Although we appreciate that under some conditions these assumptions may not be valid, for instance in some tumour cells [25,26], a body of evidence suggests that these assumptions are reasonable for normal cells.”
BackgroundACLY and ACC1 Regulate Hypoxia-Induced Apoptosis by Modulating ETV4 via α-ketoglutarate
Keenan, M. M., Liu, B., Tang, X., Wu, J., Cyr, D. D., Stevens, R. D., Ilkayeva, O., Huang, Z., Tollini, L. A., Murphy, S. K., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005599 · Cited by 45
Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism
Nguyen, T.-L., & Durán, R. V. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.09.026 · Cited by 45
Ten–eleven translocase: key regulator of the methylation landscape in cancer
Shekhawat, J. K., Gauba, K., Gupta, S., Choudhury, B., Purohit, P., Sharma, P., & Banerjee, M. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03641-3 · Cited by 43
“These intermediates accumulate in tumours which have mutant succinate dehydrogenase (SDH) and fumarate hydratase (FH) Krebs cycle enzymes (Pollard et al. 2005), they also impair the catalytic activity of TET enzymes.”
BackgroundNew Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma
Taïeb, D., & Pacák, K. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.08.001 · Cited by 43
“speculated that this retrograde pathway may prevent the potential detrimental effects of succinate excess on non-mitochondrial processes [57].”
Matlac, D. M., Vanova, K. H., Bechmann, N., Richter, S., Inderhees, J., Ghayee, H. K., Ge, G., Abunimer, L., WESLEY, R. A., Aherrahrou, R., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.589451 · Cited by 43
Zheng, L., Zhu, Z.-R., Sneh, T., Zhang, W.-T., Wang, Z.-Y., Wu, G., He, W., Qi, H., Wang, H., Wu, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165028 · Cited by 43
Global metabolomic profiling of uterine leiomyomas
Heinonen, H.-R., Mehine, M. M., Mäkinen, N., Pasanen, A. M., Pitkänen, E., Karhu, A., Sarvilinna, N. S., Sjöberg, J., Heikinheimo, O., Bützow, R. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.361 · Cited by 43
“…kidney cancer cell line from an HLRCC patient have detected accumulation of fumarate and succinate but have provided contradicting data on the levels of malate, aKG, and citrate (Pollard et al, 2005; Frezza et al, 2011; Tong et al, 2011; Adam et al, 2013; Yang et al, 2013; Zheng et al, 2013).”
BackgroundExtent of surgery for phaeochromocytomas in the genomic era
Rossitti, H. M., Söderkvist, P., & Gimm, O. (2018) · British journal of surgery · doi:10.1002/bjs.10744 · Cited by 43
Three autocrine feedback loops determine HIF1α expression in chronic hypoxia
Qutub, A. A., & Popel, A. S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.07.004 · Cited by 43
“It is one hypothesis that succinateworks as a product inhibitor [6,23,33,53].”
BackgroundInfluentialShankavaram, U. T., Fliedner, S. M. J., ELKAHLOUN, A. G., Barb, J. J., Munson, P. J., Huynh, T., Matro, J. C., Turková, H., Linehan, W. M., Timmers, H. J. L. M., et al. (2013) · Neoplasia · doi:10.1593/neo.122132 · Cited by 42
“Similarly, SDH dysfunction causes HIF stabilization by succinate or reactive oxygen species accumulation-mediated PHD inhibition [5,6].”
Familial and Hereditary Renal Cancer Syndromes
Coleman, J. (2008) · Urologic Clinics of North America · doi:10.1016/j.ucl.2008.07.014 · Cited by 42
From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy
Karagianni, P., Giannouli, S., & Voulgarelis, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126321 · Cited by 42
Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
“Moreover, HIF-1α and HIF-2α levels have been observed to accumulate in tumours with FH mutations [28,29], implying that the accumulation of fumarate is linked to HIF activation.”
BackgroundMitochondria: Oxygen sinks rather than sensors?
Wenger, R. H. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.047 · Cited by 42
“tumor suppressors, consistent with a constitutive HIFα activation in cancer cells with inactivation mutations of these tumor suppressors [38-40].”
BackgroundCarbonic anhydrase isozymes II, IX, and XII in uterine tumors
Hynninen, P., Parkkila, S., Huhtala, H., Pastoreková, S., Pastorek, J., Waheed, A., Sly, W. S., & Tomás, E. I. (2011) · Apmis · doi:10.1111/j.1600-0463.2011.02820.x · Cited by 41
The Warburg Phenomenon and Other Metabolic Alterations of Cancer Cells
Dakubo, G. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-11416-8_2 · Cited by 41
“Tumors with loss of fumarate hydratase activity are highly vascularized with increased HIF1a expression (Pollard et al. 2005a, b), and increased expression of glycolytic enzymes (Vanharanta et al. 2006).”
BackgroundPost-translational modifications of VDAC1 and VDAC2 cysteines from rat liver mitochondria
Saletti, R., Reina, S., Pittalà, M. G. G., Magrì, A., Cunsolo, V., Foti, S., & Pinto, V. D. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.06.007 · Cited by 41
Mapping of Succinate Dehydrogenase Losses in 2258 Epithelial Neoplasms
Miettinen, M., Sarlomo‐Rikala, M., McCue, P. A., Czapiewski, P., Langfort, R., Waloszczyk, P., Ważny, K., Biernat, W., Lasota, J. P., & Wang, Z. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31828bfdd3 · Cited by 41
Ooi, A., & Furge, K. A. (2012) · 癌症:英文版 · doi:10.5732/cjc.012.10102 · Cited by 41
Sandulache, V. C., & Myers, J. N. (2011) · Head & Neck · doi:10.1002/hed.21664 · Cited by 40
“Defects in the activity of 2 other TCA cycle enzymes, fumarate hydratase and succinate dehydrogenase, have been linked to stabilization of HIF-1a via inhibition of prolyl hydroxylases by their products.(40,41) HIF-1a transcriptional targets include the glucose transporters, hexokinase, lactate”
BackgroundParagangliomas of the Carotid Body: Current Management Protocols and Review of Literature
Naik, S. M., Shenoy, A. M., Nanjundappa, Halkud, R., Chavan, P., Sidappa, K., Amirtham, U., & Gupta, S. (2013) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-013-0249-4 · Cited by 40
Disruption of tubular Flcn expression as a mouse model for renal tumor induction
Chen, J., Huang, D., Rubera, I., Futami, K., Wang, P., Zlckert, P., Khoo, S. K., Dykema, K. J., Zhao, P., Petillo, D., et al. (2015) · Kidney International · doi:10.1038/ki.2015.177 · Cited by 41
Urayama, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1707 · Cited by 39
Zeng, L., Ai, C., Zhang, J., & Li, W. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.134961 · Cited by 39
Nalbantoğlu, S., & Karadağ, A. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114031 · Cited by 39
Targeting 2-oxoglutarate dehydrogenase for cancer treatment.
Chang, L., Chiang, S.-K., Chen, S., & Hung, M. (2022) · PubMed Central · Cited by 39
Mechanisms of tumor promotion by reactive oxygen species
Kobliakov, V. A. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910060015 · Cited by 39
Wang, F., Li, S. S., Segersvärd, R., Strömmer, L., Sundqvist, K., Holgersson, J., & Permert, J. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060489 · Cited by 39
“On the other hand, cancer cells may accumulate metabolites that directly inhibit PHD and thereby stabilize HIF-1 independent of hypoxia.(15) Cancer cells may also accelerate HIF-1 production spontaneously or in response to stimuli such as insulin, insulin-like growth factors (IGFs), and epidermal growth factor (EGF).”
BackgroundIdentification of Fumarate Hydratase Inhibitors with Nutrient-Dependent Cytotoxicity
Takeuchi, T., Schumacker, P. T., & Kozmin, S. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5101257 · Cited by 38
Molecular pathogenesis of tumorigenesis caused by succinate dehydrogenase defect
Moosavi, B., Zhu, X., Yang, W., & Yang, G. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.151057 · Cited by 38
Koski, T. A., Lehtonen, H. J., Jee, K. J., Ninomiya, S., Joosse, S. A., Vahteristo, P., Kiuru, M. H., Karhu, A., Sammalkorpi, H., Vanharanta, S., et al. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20663 · Cited by 38
“The unhydroxylated HIFs are not destroyed by the proteosome, which leads to aberrant stabilization of HIF in HLRCC renal tumors (Isaacs et al., 2005; Pollard et al., 2005).”
BackgroundTUFM is a potential new prognostic indicator for colorectal carcinoma
Shi, H., Hayes, M. T., Kirana, C., Miller, R. J., Keating, J. P., Macartney-Coxson, D. P., & Stubbs, R. (2012) · Pathology · doi:10.1097/pat.0b013e3283559cbe · Cited by 38
Lussey‐Lepoutre, C., Bellucci, A., Burnichon, N., Amar, L., Buffet, A., Drossart, T., Fontaine, S., Clémеnt, O., Bénit, P., Rustin, P., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04633-9 · Cited by 38
Self-citationRegulated Function of the Prolyl-4-Hydroxylase Domain (PHD) Oxygen Sensor Proteins
Nytko, K. J., Spielmann, P., Camenisch, G., Wenger, R. H., & Stiehl, D. P. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1683 · Cited by 37
“Endogenous tricarboxylic acid cycle intermediates and reactive oxygen species (ROS) have been reported to inhibit PHD function and hence link mitochondrial function with PHD-dependent oxygen sensing (12, 15, 43, 48).”
Novel insight into the Warburg effect: Sweet temptation
Zhang, H., Liu, S., Fu, S., Zhao, Q., Wang, Y., Yuan, Y., & Zhang, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104844 · Cited by 37
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 37
“Despite the fact that Pollard et al. (2005, 2006) found relatively more common HIF2a overexpression in VHL PHEOs and PGLs, whereas in SDHx-related tumors nuclear HIF1a staining was more prominent, Gimenez-Roqueplo et al. (2001, 2002) described overexpression of HIF2a and VEGF in patients with PHEOs…”
The Emerging Role of Succinate Dehyrogenase Genes (SDHx) in Tumorigenesis
Nazar, E., Khatami, F., Saffar, H., & Tavangar, S. M. (2019) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v13i2.692 · Cited by 37
Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach
Sarkadi, B., Saskői, É., Butz, H., & Patócs, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031450 · Cited by 37
Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma
Korpershoek, E., Petri, B., van Nederveen, F. H., Dinjens, W. N. M., Verhofstad, A. A. J., de Herder, W. W., Schmid, S., Perren, A. A., Komminoth, P., & de Krijger, R. R. (2007) · Endocrine Related Cancer · doi:10.1677/erc-06-0044 · Cited by 37
“Since the frequency of the H50R substitution in our series (4% of all patients) is comparable with the frequency that has been reported in the literature for the normal population, we considered it a polymorphism ( Perren et al. 2002, Cascon et al. 2003).”
BackgroundResultWarburg and Krebs and related effects in cancer
Unterlass, J. E., & Curtin, N. J. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.4 · Cited by 37
Ahvenainen, T., Tolvanen, J., Kämpjärvi, K., Uimari, O., Ahtikoski, A., Mäkinen, N., Heikinheimo, O., Aaltonen, L. A., Karhu, A., Bützow, R., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001826 · Cited by 36
Zhang, D., Wang, W., Xiang, B., Li, N., Huang, S., Zhou, W., Sun, Y., Wang, X., Ma, J., Li, G., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-0781-4 · Cited by 36
Dorai, T., Sawczuk, I. S., Pastorek, J., Wiernik, P. H., & Dutcher, J. P. (2006) · Cancer Investigation · doi:10.1080/07357900601062321 · Cited by 36
“Second, fumarate hydratase deficiency has been shown to create a secondary accumulation of succinate in a recent study (124).”
BackgroundMechanisms regulating immune surveillance of cellular stress in cancer
Seelige, R., Searles, S. C., & Bui, J. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2597-7 · Cited by 38
“In these cancers, levels of succinate are elevated, and so are HIF-1α and HIF-1α-related genes, suggesting that hypoxic pathways are also activated in these cancers [131].”
BackgroundFliedner, S. M. J., Kaludercic, N., Jiang, X.-S., Hansíková, H., Hájková, Z., Sládková, J., Limpuangthip, A., Backlund, P. S., WESLEY, R. A., Martiniova, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040949 · Cited by 37
“Accumulation of succinate and/or possibly ROS, due to enzyme malfunction, leads to inhibition of hypoxiainducible factor (HIF) prolyl hydroxylases [19,20].”
BackgroundHypothesis: solid tumours behave as systemic metabolic dictators
Lee, Y., Chang, W., & Ma, W. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12794 · Cited by 35
“Mutations in FH are responsible for the development of leiomyoma, leiomyosarcoma and renal clear cell carcinoma [41, 42].”
BackgroundPheochromocytomas and Paragangliomas: Bypassing Cellular Respiration
Cascón, A., Remacha, L., Calsina, B., & Robledo, M. (2019) · Cancers · doi:10.3390/cancers11050683 · Cited by 35
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 35
Mitochondria and the permeability transition pore in cancer metabolic reprogramming
Guo, L. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114537 · Cited by 36
Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma
Her, Y. F., Nelson-Holte, M. H., & Maher, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127471 · Cited by 35
“It has been reported that SDHB protein loss accompanies any disruption of the SDH complex in PGLs [43,44].”
BackgroundInfluentialCazzaniga, M., & Bonanni, B. (2015) · BioMed Research International · doi:10.1155/2015/972193 · Cited by 36
Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples
Gonçalves, S., Paupe, V., Dassa, E. P., Brière, J.-J., Favier, J., Gimenez‐Roqueplo, A., Bénit, P., & Rustin, P. (2010) · BMC Biochemistry · doi:10.1186/1471-2091-11-5 · Cited by 35
“Organic acid accumulation has been proven instrumental in initiating tumor formation related to SDH or fumarase deficiency [9].”
BackgroundSelf-citationSurvival of the fittest: metabolic adaptations in cancer
Berardi, M. J., & Fantin, V. R. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.001 · Cited by 36
Tena, I., Gupta, G., Tajahuerce, M., Benavent, M., Cifrián, M., Falcón, A., Fonfría, M., Olmo-García, M. I. D., Reboll, R., Conde-Moreno, A. J., et al. (2018) · Clinical Medicine Insights Oncology · doi:10.1177/1179554918763367 · Cited by 35
Tseng, P., Chen, C., Hu, K.-H., Cheng, H.-C., Lin, Y.-H., Tsai, W., Cheng, T., Wu, W.-H., Yeh, C., Lin, C.-C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24855 · Cited by 36
The Evolving Role of Succinate in Tumor Metabolism: An 18F-FDG–Based Study
Garrigue, P., Bodin-Hullin, A., Balasse, L., Fernandez-Sauze, S., Essamet, W., Dignat‐George, F., Pacák, K., Guillet, B. A., & Taïeb, D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.192674 · Cited by 34
“It has been speculated that this retrograde pathway may prevent the potential detrimental effects of succinate excess on nonmitochondrial processes (41).”
BackgroundCancer metabolomics in basic science perspective
Kwon, H. N., Oh, S., Jin, X., An, Y., & Park, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0552-4 · Cited by 34
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome
Vahteristo, P., Koski, T. A., Näätsaari, L., Kiuru, M. H., Karhu, A., Herva, R., Sallinen, S., Kuismin, O., Björck, E., Richard, S., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9312-2 · Cited by 34
Novel Pathways and Molecular Targets for the Treatment of Sarcoma
Frith, A. E., Hirbe, A. C., & Tine, B. A. V. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0319-3 · Cited by 34
Corrado, M., Scorrano, L., & Campello, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8727 · Cited by 35
“Pseudo-hypoxia enhances cancer formation and aggressiveness [54],[55].”
Verma, A. M. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232895.28674.79 · Cited by 34
Bardella, C., Olivero, M., Lorenzato, A., Geuna, M., Adam, J., O'Flaherty, L., Rustin, P., Tomlinson, I., Pollard, P. J., & Di Renzo, M. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06160-11 · Cited by 33
“onstrated previously that in FH-defective cells and MCUL/ HLRCC tumors (42, 44), the HIF- subunits are stabilized and HIF-dependent transcription is induced.”
BackgroundResultInfluentialSelf-citationRedox imbalance and hypoxia‐inducible factors: a multifaceted crosstalk
Ravi, R., & Singh, J. (2025) · FEBS Journal · doi:10.1111/febs.70013 · Cited by 33
“TCA metabolites, including succinate, fuma-rate, isocitrate, and oxaloacetate, inhibit PHD enzymes by competing with their substrate, α -ketoglutarate [31,39 – 42].”
Fumarase is involved in DNA double-strand break resection through a functional interaction with Sae2
Leshets, M., Ramamurthy, D., Lisby, M., Lehming, N., & Pines, O. (2017) · Current Genetics · doi:10.1007/s00294-017-0786-4 · Cited by 33
Targeting respiratory complex I to prevent the Warburg effect
Vatrinet, R., Iommarini, L., Kurelac, I., Luise, M. D., Gasparre, G., & Porcelli, A. M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.01.017 · Cited by 33
Downregulation of SRF–FOS–JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas
Raimundo, N., Vanharanta, S., Aaltonen, L. A., Hovatta, I., & Suomalainen, A. (2009) · Oncogene · doi:10.1038/onc.2008.472 · Cited by 33
“…of the oxidative ATP production pathway due to the lack of the activity of a key metabolic enzyme FH. FH-deficient leiomyomas have also been shown to activate hypoxia response through HIF1-a pathway induction (Eng et al., 2003; Pollard et al., 2003, 2005a, b, 2007; Isaacs et al., 2005).”
Kuo, C., Cheng, C.-T., Hou, P., Lin, Y.-P., Ma, H., Chung, Y., Chi, K. K., Chen, Y., Li, W., Kung, H.-J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8570 · Cited by 33
“Because succinate and fumarate are known to inhibit PHD2 [28, 31, 32], their accumulation in the DKG-treated cells corroborated our previous observations that DKG stabilized HIF-1α through inhibiting PHD2-mediated hydroxylation [37].”
Self-citationSuccinate, increased in metabolic syndrome, activates GPR91 receptor signaling in urothelial cells
Mossa, A. H., Flores, M. V., Cammisotto, P., & Campeau, L. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.05.014 · Cited by 33
Testa, U., Pelosi, E., & Castelli, G. (2020) · Medicines · doi:10.3390/medicines7080044 · Cited by 33
Fumarate drives EMT in renal cancer
Sciacovelli, M., & Frezza, C. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.137 · Cited by 33
Park, H., Ohshima, K., Nojima, S., Tahara, S., Kurashige, M., Hori, Y., Okuzaki, D., Wada, N., Ikeda, J., & Morii, E. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0017-0 · Cited by 32
Differential metabolic consequences of fumarate hydratase and respiratory chain defects
Raimundo, N., Ahtinen, J., Fumić, K., Barić, I., Remes, A. M., Renkonen, R., Lapatto, R., & Suomalainen, A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.008 · Cited by 32
Rapizzi, E., Ercolino, T., Fucci, R., Zampetti, B., Felici, R., Guasti, D., Morandi, A., Giannoni, E., Giaché, V., Bani, D., et al. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0172-3 · Cited by 32
Risk‐Oriented Approach to Hereditary Adrenal Pheochromocytoma
Machens, A., Brauckhoff, M., Gimm, O., & Dralle, H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.045 · Cited by 32
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer
Yang, J., Harris, A. L., & Davidoff, A. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010240 · Cited by 32
Mitochondrial Deficiencies in the Predisposition to Paraganglioma
Lussey‐Lepoutre, C., Buffet, A., Gimenez‐Roqueplo, A., & Favier, J. (2017) · Metabolites · doi:10.3390/metabo7020017 · Cited by 32
Bacterial fumarase and L-malic acid are evolutionary ancient components of the DNA damage response
Singer, E., Silas, Y., Ben‐Yehuda, S., & Pines, O. (2017) · eLife · doi:10.7554/elife.30927 · Cited by 31
“…example of such a scenario are succinate and fumarate that can inhibit prolyl hydroxylases (PHDs), resulting in the stabilization of HIF1-a and activation of downstream hypoxic pathways in human cells (Gottlieb and Tomlinson, 2005; Isaacs et al., 2005; Pollard et al., 2005; Sudarshan et al., 2007).”
BackgroundHypoxia-driven metabolic reprogramming of adipocytes fuels cancer cell proliferation
Aird, R., Wills, J. C., Roby, K. F., Bénézech, C., Stimson, R. H., Wabitsch, M., Pollard, J. W., Finch, A. J., & Michailidou, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.989523 · Cited by 30
Interplay between hypoxia inducible Factor-1 and mitochondria in cardiac diseases
Mialet‐Perez, J., & Belaïdi, E. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.04.239 · Cited by 31
Lin, A., Anderson, S. L., Minard, K. I., & McAlister-Henn, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.266890 · Cited by 30
Diagnostic Approach to Hereditary Renal Cell Carcinoma
Gupta, S., Kang, H. C., Ganeshan, D., Bathala, T. K., & Kundra, V. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.13514 · Cited by 30
“Mutations in fumarate hydratase and succinate dehydrogenase (SDH) result in accumulation of fumarate and succinate, stabilization of HIF-1α, and activation of hypoxia-inducible genes [5, 22].”
BackgroundCo-opting a Bioorthogonal Reaction for Oncometabolite Detection
Zengeya, T. T., Garlick, J. M., Kulkarni, R. A., Miley, M., Roberts, A. M., Yang, Y., Crooks, D. R., Sourbier, C., Linehan, W. M., & Meier, J. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09706 · Cited by 30
Zeng, L., Ai, C., Zheng, J., Zhang, J., & Li, W.-C. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.06.047 · Cited by 30
Glod, J. W., Arnaldez, F. I., Wiener, L. S., Spencer, M., Killian, J. K., Meltzer, P. S., Dombi, E., Derse‐Anthony, C., Derdak, J., Srinivasan, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0986 · Cited by 30
Pheochromocytoma: Gasping for Air
Jochmanová, I., Zhuang, Z., & Pacák, K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0231-4 · Cited by 30
Increased HIF1α in SDH and FH deficient tumors does not cause microsatellite instability
Lehtonen, H. J., Mäkinen, M. J., Kiuru, M. H., Laiho, P., Herva, R., van Minderhout, I. J. H. M., Hogendoorn, P. C. W., Cornelisse, C. J., Devilee, P., Launonen, V., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22819 · Cited by 30
Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS
Tabebi, M., Dutta, R. K., Skoglund, C., Söderkvist, P., & Gimm, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010560 · Cited by 29
Tumour microenvironment in pheochromocytoma and paraganglioma
Martinelli, S., Amore, F., Canu, L., Maggi, M., & Rapizzi, E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137456 · Cited by 29
Kidney Cancer Pathology in the New Context of Targeted Therapy
Allory, Y., Culine, S., & TAILLE, A. D. L. (2011) · Pathobiology · doi:10.1159/000315543 · Cited by 29
Signals from the Circle: Tricarboxylic Acid Cycle Intermediates as Myometabokines
Maurer, J., Hoene, M., & Weigert, C. (2021) · Metabolites · doi:10.3390/metabo11080474 · Cited by 31
“A transcriptome analysis of livers of exercising mice pointed to HIF1α and cAMP as positive regulators of the acute transcriptional response to endurance exercise [39].”
Background
Metadata
- Authors
- Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., & Tomlinson, I. P. M.
- Affiliations
- St Thomas' Hospital (GB)
- Cancer Research UK (GB)
- Sheffield Children's Hospital (GB)
- University Hospital of Wales (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- St George's Hospital (GB)
- Guy's Hospital (GB)
- Inserm (FR)
- Corresponding author
- Pollard, P.J.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-29
- Volume
- 14
- Issue
- 15
- Pages
- 2231-2239
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2136749294
- Cited by
- 865
- References
- 39
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 15 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 37 · 2019: 56 · 2018: 48 · 2017: 34 · 2016: 47 · 2015: 58 · 2014: 52 · 2013: 55 · 2012: 48
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- fumarate hydratase, succinate dehydrogenase, Krebs cycle intermediates, fumarate accumulation, succinate accumulation, HIF-1α stabilization, hereditary leiomyomatosis and renal cell carcinoma, paraganglioma, pheochromocytoma, leiomyoma, microvessel density, vascular endothelial growth factor, reactive oxygen species
- MeSH terms
- Carcinoma, Renal Cell, Citric Acid Cycle, Female, Fumarate Hydratase, Humans, Leiomyoma, Neoplasms, Paraganglioma, Succinate Dehydrogenase, Tumor Cells, Cultured, Germ-Line Mutation, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.